NASDAQ:ANGO AngioDynamics (ANGO) Stock Forecast, Price & News $9.98 +0.34 (+3.53%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$9.75▼$10.3250-Day Range$8.29▼$12.4752-Week Range$8.18▼$24.74Volume432,640 shsAverage Volume246,705 shsMarket Capitalization$391.62 millionP/E RatioN/ADividend YieldN/APrice Target$24.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability AngioDynamics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside140.5% Upside$24.00 Price TargetShort InterestHealthy2.01% of Float Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment1.04Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.05) to $0.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.72 out of 5 starsMedical Sector65th out of 983 stocksSurgical & Medical Instruments Industry6th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingAngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, AngioDynamics has a forecasted upside of 140.5% from its current price of $9.98.Amount of Analyst CoverageAngioDynamics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.01% of the float of AngioDynamics has been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently decreased by 7.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAngioDynamics has received a 59.93% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ultrasound machines", "Clinical laser systems", and "Intravenous therapy equipment" products. See details.Environmental SustainabilityThe Environmental Impact score for AngioDynamics is -0.99. Previous Next 3.4 News and Social Media Coverage News SentimentAngioDynamics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for AngioDynamics this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added AngioDynamics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions94.94% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for AngioDynamics are expected to grow in the coming year, from ($0.05) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is -10.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is -10.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AngioDynamics (NASDAQ:ANGO) StockAngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.Read More Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANGO Stock News HeadlinesMay 30, 2023 | americanbankingnews.comZacks Research Research Analysts Boost Earnings Estimates for AngioDynamics, Inc. (NASDAQ:ANGO)May 29, 2023 | americanbankingnews.comAngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 7.1% in MayJune 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 19, 2023 | fool.comAngioDynamics (NASDAQ: ANGO)May 18, 2023 | americanbankingnews.comAngioDynamics (NASDAQ:ANGO) Earns Hold Rating from Analysts at StockNews.comMay 17, 2023 | americanbankingnews.comAngioDynamics, Inc. (NASDAQ:ANGO) Short Interest UpdateMay 15, 2023 | finance.yahoo.comIs the Options Market Predicting a Spike in AngioDynamics (ANGO) Stock?April 18, 2023 | msn.comRaymond James Downgrades AngioDynamics (ANGO)June 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.April 18, 2023 | americanbankingnews.comResearch Analysts Offer Predictions for AngioDynamics, Inc.'s FY2023 Earnings (NASDAQ:ANGO)April 17, 2023 | americanbankingnews.comRaymond James Downgrades AngioDynamics (NASDAQ:ANGO) to OutperformApril 14, 2023 | americanbankingnews.comAngioDynamics, Inc. (NASDAQ:ANGO) to Post Q4 2023 Earnings of $0.02 Per Share, Zacks Research ForecastsApril 14, 2023 | americanbankingnews.comHead-To-Head Analysis: AngioDynamics (NASDAQ:ANGO) and Vivos (OTCMKTS:RDGL)April 10, 2023 | finance.yahoo.comImplied Volatility Surging for AngioDynamics (ANGO) Stock OptionsApril 5, 2023 | americanbankingnews.comKeyCorp Comments on AngioDynamics, Inc.'s Q4 2023 Earnings (NASDAQ:ANGO)April 4, 2023 | finance.yahoo.comWall Street Thinks This Small-Cap Stock Can Double in ValueApril 3, 2023 | americanbankingnews.comAngioDynamics (NASDAQ:ANGO) PT Lowered to $14.00 at Raymond JamesApril 1, 2023 | finance.yahoo.comAngioDynamics, Inc. (NASDAQ:ANGO) Q3 2023 Earnings Call TranscriptApril 1, 2023 | americanbankingnews.comAngioDynamics (NASDAQ:ANGO) Issues FY 2023 Earnings GuidanceApril 1, 2023 | americanbankingnews.comAngioDynamics (NASDAQ:ANGO) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPSMarch 30, 2023 | finance.yahoo.comAngioDynamics (ANGO) Reports Q3 Loss, Lags Revenue EstimatesMarch 30, 2023 | benzinga.comWhy AngioDynamics Shares Are Trading Lower TodayMarch 30, 2023 | finance.yahoo.comAngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises GuidanceMarch 30, 2023 | seekingalpha.comAngioDynamics Non-GAAP EPS of -$0.03 misses by $0.02, revenue of $80.7M misses by $2.49MMarch 28, 2023 | americanbankingnews.comAngioDynamics (ANGO) Scheduled to Post Earnings on ThursdayMarch 26, 2023 | cnbc.comThe Street awaits key inflation report next week as banking worries persistMarch 18, 2023 | finance.yahoo.comShareholders in AngioDynamics (NASDAQ:ANGO) are in the red if they invested a year agoSee More Headlines ANGO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANGO Company Calendar Last Earnings3/30/2023Today6/03/2023Next Earnings (Estimated)7/11/2023Fiscal Year End5/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ANGO CUSIP03475V10 CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees800Year Founded1988Price Target and Rating Average Stock Price Forecast$24.00 High Stock Price Forecast$35.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+140.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,550,000.00 Net Margins-11.13% Pretax Margin-11.74% Return on Equity-0.71% Return on Assets-0.52% Debt Debt-to-Equity Ratio0.13 Current Ratio2.19 Quick Ratio1.28 Sales & Book Value Annual Sales$316.22 million Price / Sales1.24 Cash Flow$0.78 per share Price / Cash Flow12.80 Book Value$10.96 per share Price / Book0.91Miscellaneous Outstanding Shares39,240,000Free Float37,313,000Market Cap$391.62 million OptionableOptionable Beta0.60 Social Links Key ExecutivesJames Christopher ClemmerPresident, Chief Executive Officer & DirectorDavid D. HelselSVP-Global Operations, Research & DevelopmentStephen A. TrowbridgeChief Financial Officer & Executive Vice PresidentKim L. SeaburySenior Vice President-Information TechnologyJuan Carlos SernaSenior VP-Scientific & Clinical AffairsKey CompetitorsAccurayNASDAQ:ARAYSurmodicsNASDAQ:SRDXOrthofix MedicalNASDAQ:OFIXCardiovascular SystemsNASDAQ:CSIICerusNASDAQ:CERSView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 13,063 shares on 6/1/2023Ownership: 0.033%Ameriprise Financial Inc.Bought 13,669 shares on 5/22/2023Ownership: 0.742%Putnam Investments LLCBought 1,876 shares on 5/22/2023Ownership: 0.077%JPMorgan Chase & Co.Sold 123,382 shares on 5/18/2023Ownership: 0.585%New York State Common Retirement FundSold 8,786 shares on 5/18/2023Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions ANGO Stock - Frequently Asked Questions Should I buy or sell AngioDynamics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ANGO shares. View ANGO analyst ratings or view top-rated stocks. What is AngioDynamics' stock price forecast for 2023? 1 brokers have issued 12-month price objectives for AngioDynamics' stock. Their ANGO share price forecasts range from $13.00 to $35.00. On average, they anticipate the company's share price to reach $24.00 in the next twelve months. This suggests a possible upside of 140.5% from the stock's current price. View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts. How have ANGO shares performed in 2023? AngioDynamics' stock was trading at $13.77 at the beginning of the year. Since then, ANGO shares have decreased by 27.5% and is now trading at $9.98. View the best growth stocks for 2023 here. Are investors shorting AngioDynamics? AngioDynamics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 761,800 shares, a drop of 7.1% from the April 30th total of 820,300 shares. Based on an average trading volume of 334,300 shares, the short-interest ratio is currently 2.3 days. Currently, 2.0% of the company's shares are sold short. View AngioDynamics' Short Interest. When is AngioDynamics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 11th 2023. View our ANGO earnings forecast. How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) issued its earnings results on Thursday, March, 30th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.02. The medical instruments supplier earned $80.70 million during the quarter, compared to analyst estimates of $83.20 million. AngioDynamics had a negative trailing twelve-month return on equity of 0.71% and a negative net margin of 11.13%. The company's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period last year, the firm earned $0.03 earnings per share. What ETFs hold AngioDynamics' stock? ETFs with the largest weight of AngioDynamics (NASDAQ:ANGO) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco Raymond James SB-1 Equity ETF (RYJ), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco S&P SmallCap Health Care ETF (PSCH), Global X Aging Population ETF (AGNG), SPDR S&P Kensho New Economies Composite ETF (KOMP), Principal Healthcare Innovators ETF (BTEC) and iShares U.S. Medical Devices ETF (IHI). What guidance has AngioDynamics issued on next quarter's earnings? AngioDynamics updated its FY 2023 earnings guidance on Friday, March, 31st. The company provided earnings per share (EPS) guidance of -$0.06--$0.01 for the period, compared to the consensus estimate of -$0.01. The company issued revenue guidance of $338.00 million-$342.00 million, compared to the consensus revenue estimate of $342.47 million. What is James C. Clemmer's approval rating as AngioDynamics' CEO? 34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX). What is AngioDynamics' stock symbol? AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO." Who are AngioDynamics' major shareholders? AngioDynamics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.57%), Victory Capital Management Inc. (9.86%), Dimensional Fund Advisors LP (6.33%), State Street Corp (5.29%), Systematic Financial Management LP (3.58%) and Paradigm Capital Management Inc. NY (2.22%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AngioDynamics' stock price today? One share of ANGO stock can currently be purchased for approximately $9.98. How much money does AngioDynamics make? AngioDynamics (NASDAQ:ANGO) has a market capitalization of $391.62 million and generates $316.22 million in revenue each year. The medical instruments supplier earns $-26,550,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. How many employees does AngioDynamics have? The company employs 800 workers across the globe. Does AngioDynamics have any subsidiaries? The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.Read More How can I contact AngioDynamics? AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The official website for the company is www.angiodynamics.com. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at mpolyviou@evcgroup.com, or via fax at 518-795-1401. This page (NASDAQ:ANGO) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.